Headwinds continue to hit both the global and domestic markets. As the situation is unlikely to improve anytime soon, we may see a further ...

HRV Pharma CEO Hari Kiran Chereddi says investing in capacity at partner facilities, exploring acquisitions for market access; forecasts Rs...

At a time when fears of AI are gripping the public, the startup has built a wet lab, or place for physical experiments, in the San Francisc...

Mutual funds raised their healthcare allocation for the fourth straight month in August 2026 to 8.4%, the highest in 71 months. Experts att...

In the stock market, when a big theme or sectoral trend takes off, most investors focus on the face of it. A brand with which they can rela...

If you are an investor with some skin in the game, be ready to see some underperformance. Why? Because valuation readjustment can take more...

PGIM India Healthcare Fund generated a 22% return over the past year by over-allocating to high-growth segments like CDMO, specialty pharma...

Invesco India has unveiled an innovative pharma and healthcare fund tailored for investors seeking opportunities in India's burgeoning heal...

Invesco Mutual Fund has launched a new open-ended equity scheme. This fund will invest in India's evolving pharma and healthcare sectors. I...

Apart from IT, the domestic pharma industry is also worried over President Obama's proposal to end tax breaks for US companies, which are e...

With Barack Obama's election as the President of the United States, outsourcing of activities from the US to the Indian pharma industry mig...

Ajay Piramal, chairman of Piramal Healthcare, spoke to ET about the company’s plans.

With global pharma companies waking up to technology outsourcing services as a tool to reduce the time to market of their R&D harvest.

Small and mid-size pharma companies focused on outsourcing seem to have caught the attention of investors, if the recent investments by pri...

INDIAN pharmaceutical companies are outsourcing a portion of their medical representative workforce, in a bid to become more competitive.

Clinical Research outsourcing (CRO) is a young industry worth about 118 million dollars a year in India, but it is growing fast.

After BPOs & KPOs, outsourcing segments are all set to move towards Research Process Outsourcing (RPO).